IBDEI1D7 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22752,1,4,0)
 ;;=4^D57.819
 ;;^UTILITY(U,$J,358.3,22752,2)
 ;;=^5002320
 ;;^UTILITY(U,$J,358.3,22753,0)
 ;;=D57.3^^104^1061^7
 ;;^UTILITY(U,$J,358.3,22753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22753,1,3,0)
 ;;=3^Sickle-Cell Trait
 ;;^UTILITY(U,$J,358.3,22753,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,22753,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,22754,0)
 ;;=D57.20^^104^1061^8
 ;;^UTILITY(U,$J,358.3,22754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22754,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,22754,1,4,0)
 ;;=4^D57.20
 ;;^UTILITY(U,$J,358.3,22754,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,22755,0)
 ;;=D56.8^^104^1061^9
 ;;^UTILITY(U,$J,358.3,22755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22755,1,3,0)
 ;;=3^Thalassemias
 ;;^UTILITY(U,$J,358.3,22755,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,22755,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,22756,0)
 ;;=D57.40^^104^1061^6
 ;;^UTILITY(U,$J,358.3,22756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22756,1,3,0)
 ;;=3^Sickle-Cell Thalassemia w/o Crisis
 ;;^UTILITY(U,$J,358.3,22756,1,4,0)
 ;;=4^D57.40
 ;;^UTILITY(U,$J,358.3,22756,2)
 ;;=^329908
 ;;^UTILITY(U,$J,358.3,22757,0)
 ;;=C91.01^^104^1062^20
 ;;^UTILITY(U,$J,358.3,22757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22757,1,3,0)
 ;;=3^Lymphoblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,22757,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,22757,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,22758,0)
 ;;=C91.00^^104^1062^21
 ;;^UTILITY(U,$J,358.3,22758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22758,1,3,0)
 ;;=3^Lymphoblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,22758,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,22758,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,22759,0)
 ;;=C92.41^^104^1062^41
 ;;^UTILITY(U,$J,358.3,22759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22759,1,3,0)
 ;;=3^Promyleocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,22759,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,22759,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,22760,0)
 ;;=C92.01^^104^1062^32
 ;;^UTILITY(U,$J,358.3,22760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22760,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,22760,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,22760,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,22761,0)
 ;;=C92.51^^104^1062^35
 ;;^UTILITY(U,$J,358.3,22761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22761,1,3,0)
 ;;=3^Myelomonocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,22761,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,22761,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,22762,0)
 ;;=C91.11^^104^1062^24
 ;;^UTILITY(U,$J,358.3,22762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22762,1,3,0)
 ;;=3^Lymphocytic B-Cell Type Leukemia,Chr,In Remission
 ;;^UTILITY(U,$J,358.3,22762,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,22762,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,22763,0)
 ;;=C91.10^^104^1062^25
 ;;^UTILITY(U,$J,358.3,22763,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22763,1,3,0)
 ;;=3^Lymphocytic B-Cell Type Leukemia,Chr,Not in Remission
 ;;^UTILITY(U,$J,358.3,22763,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,22763,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,22764,0)
 ;;=C92.11^^104^1062^33
 ;;^UTILITY(U,$J,358.3,22764,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22764,1,3,0)
 ;;=3^Myeloid Leukemia,BCR/ABL-Positive,Chr,In Remission
 ;;^UTILITY(U,$J,358.3,22764,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,22764,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,22765,0)
 ;;=C92.10^^104^1062^34
 ;;^UTILITY(U,$J,358.3,22765,1,0)
 ;;=^358.31IA^4^2
